Targets and investigative treatments for primary biliary cholangitis

References

• Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386:1565–1575.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56:1181–1188.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Gaouar F, Chretien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 2012;56:218–224.
   PubMed Web of Science ®Google Scholar
• Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194–1202.
   PubMed Web of Science ®Google Scholar
• Parikh-Patel A, Gold EB, Worman H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology. 2001;33:16–21.
   PubMed Web of Science ®Google Scholar
• Cordell HJ, Han Y, Mells GF, et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun. 2015;6:8019.
   PubMed Web of Science ®Google Scholar
• Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044–1051.
   PubMed Web of Science ®Google Scholar
• Newton JL. Fatigue in primary biliary cirrhosis. Clin Liver Dis. 2008;12:367–83; ix.
   PubMed Web of Science ®Google Scholar
• Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399–407.
   PubMed Web of Science ®Google Scholar
• Quarneti C, Muratori P, Lalanne C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int. 2015;35:636–641.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308.
   PubMed Web of Science ®Google Scholar
• Mattalia A, Quaranta S, Leung PS, et al. Characterization of antimitochondrial antibodies in health adults. Hepatology. 1998;27:656–661.
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Alessio MG, Smyk DS, et al. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol. 2012;12:92.
   PubMed Web of Science ®Google Scholar
• Hu S, Zhao F, Wang Q, et al. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clin Chem Lab Med. 2014;52:1533–1542.
   PubMed Web of Science ®Google Scholar
• Leung PS, Rossaro L, Davis PA, et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007;46:1436–1442.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Pares A, Jara LJ, et al. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat. 2005;12:648–654.
   PubMed Web of Science ®Google Scholar
• Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol. 2003;1:89–95.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Brunt EM, Heathcote J, et al. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52:349–359.
   PubMed Web of Science ®Google Scholar
• Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644–647.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 1996;110:1515–1518.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884–890.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994;330:1342–1347.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137–1140.
   PubMed Web of Science ®Google Scholar
• Combes B, Carithers RL Jr., Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759–766.
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–720.
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281–1287.
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000;32:561–566.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Bonnand AM, Chretien Y, et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology. 1999;29:1668–1671.
   PubMed Web of Science ®Google Scholar
• Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799–1807.
   PubMed Web of Science ®Google Scholar
• Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354:1053–1060.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
   PubMed Web of Science ®Google Scholar
• Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology. 1976;70:656–660.
   PubMed Web of Science ®Google Scholar
• Matloff DS, Alpert E, Resnick RH, et al. A prospective trial of D-penicillamine in primary biliary cirrhosis. N Engl J Med. 1982;306:319–326.
   PubMed Web of Science ®Google Scholar
• Hishon S, Tobin G, Ciclitira PJ. A clinical trial of levamisole in primary biliary cirrhosis. Postgrad Med J. 1982;58:701–703.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Davis GL, Schafer DF, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology. 1986;91:1327–1334.
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med. 1986;315:1448–1454.
   PubMed Web of Science ®Google Scholar
• Mitchison HC, Bassendine MF, Malcolm AJ, et al. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology. 1989;10:420–429.
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Ludwig J, Lindor KD, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 1990;322:1419–1424.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290.
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149–1156.
   PubMed Web of Science ®Google Scholar
• Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324:1548–1554.
   PubMed Web of Science ®Google Scholar
• Raedsch R, Stiehl A, Walker S, et al. [Combined ursodeoxycholic acid plus colchicine – treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study]. Z Gastroenterol. 1992;30(Suppl 1):55–57.
   PubMedGoogle Scholar
• McCormick PA, Scott F, Epstein O, et al. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol. 1994;21:496–499.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology. 1995;22:1158–1162.
   PubMed Web of Science ®Google Scholar
• Leuschner M, Guldutuna S, You T, et al. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol. 1996;25:49–57.
   PubMed Web of Science ®Google Scholar
• Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;31:318–323.
   PubMed Web of Science ®Google Scholar
• Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918–925.
   PubMed Web of Science ®Google Scholar
• Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005;41:747–752.
   PubMed Web of Science ®Google Scholar
• Angulo P, Patel T, Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;32:897–900.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2005;39:168–171.
   PubMed Web of Science ®Google Scholar
• Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2010;44:371–373.
   PubMed Web of Science ®Google Scholar
• Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33:235–242.
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Florentin M, Elisaf MS, et al. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J. 2010;4:120–126.
   PubMedGoogle Scholar
• Ohira H, Sato Y, Ueno T, et al. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol. 2002;97:2147–2149.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther. 2015;9:2757–2766.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012;55:512–521.
   PubMed Web of Science ®Google Scholar
• Mason AL, Lindor KD, Bacon BR, et al. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther. 2008;28:886–894.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(751–61):e8.
   Google Scholar
• Hirschfield GM, Gershwin ME, Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64:189–199.
   PubMed Web of Science ®Google Scholar
• Wang L, Han Q, Chen H, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev. 2014;23:2482–2489.
   PubMed Web of Science ®Google Scholar
• Wang L, Li J, Liu H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013;28(Suppl 1):85–92.
   PubMed Web of Science ®Google Scholar
• Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338-49e5; quiz e15.
   PubMed Web of Science ®Google Scholar
• Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115–121.
   PubMedGoogle Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–877.
   PubMed Web of Science ®Google Scholar
• Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–2194.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–1367.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368.
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.
   PubMed Web of Science ®Google Scholar
• Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8:e005.
   PubMedGoogle Scholar
• Corpechot C. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S13–20.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Boyer JL. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology. 2013;57:1691–1693.
   PubMed Web of Science ®Google Scholar
• Grigorian AY, Mardini HE, Corpechot C, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39:296–306.
   PubMed Web of Science ®Google Scholar
• Halliday JS, Chapman RW. No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue! J Gastroenterol Hepatol. 2011;26:1345–1346.
   PubMed Web of Science ®Google Scholar
• Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis. 2012;13:219–224.
   PubMed Web of Science ®Google Scholar
• Iwasaki S, Tsuda K, Ueta H. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatology Research. 1999;16:12–18.
   Web of Science ®Google Scholar
• Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38:573–578.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Niimi A, Maeda A, et al. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000;95:2990–2992.
   PubMed Web of Science ®Google Scholar
• Lens S, Leoz M, Nazal L, et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 2014;34:197–203.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Ananthanarayanan M, Soroka CJ, et al. Peroxisome proliferator-activated receptor alpha activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology. 2014;59:1030–1042.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Assis DN, Boyer JL. On fibrates and cholestasis: a review. Hepatology. 2015;62(2):635–643.
   PubMed Web of Science ®Google Scholar
• Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis. Drug Des Devel Ther. 2015;9:5407–5419.
   PubMed Web of Science ®Google Scholar
• Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110:423–431.
   PubMed Web of Science ®Google Scholar
• Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43:283–293.
   PubMed Web of Science ®Google Scholar
• Hegade VS, Khanna A, Walker LJ, et al. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci. 2016. doi:10.1007/s10620-016-4250-y. PMID: 27435324.
   PubMed Web of Science ®Google Scholar
• Banales JM, Arenas F, Rodriguez-Ortigosa CM, et al. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology. 2006;43:266–275.
   PubMed Web of Science ®Google Scholar
• Arenas F, Hervias I, Uriz M, et al. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest. 2008;118:695–709.
   PubMed Web of Science ®Google Scholar
• Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196–202.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis. 2011;31:147–156.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Lian ZX, Yang GX, et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005;128:304–312.
   PubMed Web of Science ®Google Scholar
• Moritoki Y, Lian ZX, Lindor K, et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology. 2009;50:1893–1903.
   PubMed Web of Science ®Google Scholar
• Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2013;108:933–941.
   PubMed Web of Science ®Google Scholar
• Mason A, Xu L, Neuberger J. Proof of principal studies to assess the role of the human betaretrovirus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:2499–2500.
   PubMed Web of Science ®Google Scholar
• Wang W, Indik S, Wasilenko ST, et al. Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease. Aliment Pharmacol Ther. 2015;41:393–405.
   PubMed Web of Science ®Google Scholar
• Mason AL, Farr GH, Xu L, et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:2348–2355.
   PubMed Web of Science ®Google Scholar
• Sharon D, Mason AL. Role of novel retroviruses in chronic liver disease: assessing the link of human betaretrovirus with primary biliary cirrhosis. Curr Infect Dis Rep. 2015;17:460.
   PubMed Web of Science ®Google Scholar
• Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996;271:26762–26771.
   PubMed Web of Science ®Google Scholar
• Dhirapong A, Yang GX, Nadler S, et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology. 2013;57:708–715.
   PubMed Web of Science ®Google Scholar
• Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581–1591.
   PubMed Web of Science ®Google Scholar
• Zhou M, Marc Learned R, Rossi SJ, et al. Engineered FGF19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology. 2015;63(3):929–929.
   Web of Science ®Google Scholar
• Mayo M, Wigg A, Thompson A, et al. Impact of NGM282 on the incidence and severity of pruritus in primary biliary cirrhosis patients and correlations with liver chemistries and serum bile acids. Hepatology. 2015;62(S1):520A–521A.
   Google Scholar
• Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis. 2014;46:302–312.
   PubMedGoogle Scholar
• Baghdasaryan A, Claudel T, Gumhold J, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output. Hepatology. 2011;54:1303–1312.
   PubMed Web of Science ®Google Scholar
• Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci (Landmark Ed). 2009;14:2584–2598.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57:1097–1109.
   PubMed Web of Science ®Google Scholar
• Iwaisako K, Haimerl M, Paik YH, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci USA. 2012;109:E1369–E1376.
   PubMed Web of Science ®Google Scholar